Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Nuñez, Nicolas Gonzalo; Berner, Fiamma; Friebel, Ekaterina; Unger, Susanne; Wyss, Nina; Gomez, Julia Martinez; Purde, Mette-Triin; Niederer, Rebekka; Porsch, Maximilian; Lichtensteiger, Christa; Kramer, Rafaela; Erdmann, Michael; Schmitt, Christina; Heinzerling, Lucie; Abdou, Marie-Therese; Karbach, Julia; Schadendorf, Dirk; Zimmer, Lisa; Ugurel, Selma; Klümper, Niklas; ... (2023). Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y), 4(2), 113-129.e7. Cell Press 10.1016/j.medj.2022.12.007

[img]
Preview
Text
1-s2.0-S2666634022005232-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (6MB) | Preview

BACKGROUND

Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce effective anti-tumor responses, they may also drive serious immune-related adverse events (irAEs). Identifying biomarkers to predict which patients will suffer from irAEs would enable more accurate clinical risk-benefit analysis for ICI treatment and may also shed light on common or distinct mechanisms underpinning treatment success and irAEs.

METHODS

In this prospective multi-center study, we combined a multi-omics approach including unbiased single-cell profiling of over 300 peripheral blood mononuclear cell (PBMC) samples and high-throughput proteomics analysis of over 500 serum samples to characterize the systemic immune compartment of patients with melanoma or NSCLC before and during treatment with ICIs.

FINDINGS

When we combined the parameters obtained from the multi-omics profiling of patient blood and serum, we identified potential predictive biomarkers for ICI-induced irAEs. Specifically, an early increase in CXCL9/CXCL10/CXCL11 and interferon-γ (IFN-γ) 1 to 2 weeks after the start of therapy are likely indicators of heightened risk of developing irAEs. In addition, an early expansion of Ki-67+ regulatory T cells (Tregs) and Ki-67+ CD8+ T cells is also likely to be associated with increased risk of irAEs.

CONCLUSIONS

We suggest that the combination of these cellular and proteomic biomarkers may help to predict which patients are likely to benefit most from ICI therapy and those requiring intensive monitoring for irAEs.

FUNDING

This work was primarily funded by the European Research Council, the Swiss National Science Foundation, the Swiss Cancer League, and the Forschungsförderung of the Kantonsspital St. Gallen.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Früh, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2666-6340

Publisher:

Cell Press

Language:

English

Submitter:

Pubmed Import

Date Deposited:

25 Jan 2023 13:30

Last Modified:

13 Feb 2023 00:16

Publisher DOI:

10.1016/j.medj.2022.12.007

PubMed ID:

36693381

Uncontrolled Keywords:

Translation to patients biomarkers for immunotherapy cancer immunotherapy checkpoint blockade immune-related adverse events

BORIS DOI:

10.48350/177872

URI:

https://boris.unibe.ch/id/eprint/177872

Actions (login required)

Edit item Edit item
Provide Feedback